317 related articles for article (PubMed ID: 16426593)
41. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
42. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction.
Ban CR; Twigg SM; Franjic B; Brooks BA; Celermajer D; Yue DK; McLennan SV
Diabetes Res Clin Pract; 2010 Mar; 87(3):335-41. PubMed ID: 20096949
[TBL] [Abstract][Full Text] [Related]
43. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
44. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
[TBL] [Abstract][Full Text] [Related]
45. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
46. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
47. Fasting homocysteine levels in adults with type 1 diabetes and retinopathy.
Saeed BO; Nixon SJ; White AJ; Summerfield GP; Skillen AW; Weaver JU
Clin Chim Acta; 2004 Mar; 341(1-2):27-32. PubMed ID: 14967155
[TBL] [Abstract][Full Text] [Related]
48. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
[TBL] [Abstract][Full Text] [Related]
49. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus.
Shiau MY; Tsai ST; Tsai KJ; Haung ML; Hsu YT; Chang YH
Mt Sinai J Med; 2006 Nov; 73(7):1024-8. PubMed ID: 17195891
[TBL] [Abstract][Full Text] [Related]
50. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E
J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
[TBL] [Abstract][Full Text] [Related]
51. [Clinical significance of matrix metalloproteinase-9/tissue inhibitors of matrix metalloproteinase -1 imbalance in maternal serum, amniotic fluid, umbilical cord serum in patients with premature rupture of the membranes].
Lu D; Wang ZX; Wang XL; Gu XW; Wang YX; Fu D
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):20-4. PubMed ID: 16635322
[TBL] [Abstract][Full Text] [Related]
52. Genetic polymorphism c.1562C>T of the MMP-9 is associated with macroangiopathy in type 2 diabetes mellitus.
Wang Y; Su Y; Xu Y; Pan SH; Liu GD
Biochem Biophys Res Commun; 2010 Jan; 391(1):113-7. PubMed ID: 19909726
[TBL] [Abstract][Full Text] [Related]
53. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
54. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
Szczepańska-Kostro J; Kowalewski M; Urban M; Gardziejczyk M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(4):257-60. PubMed ID: 17239302
[TBL] [Abstract][Full Text] [Related]
55. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
[TBL] [Abstract][Full Text] [Related]
56. Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases.
Mawrin C; Brunn A; Röcken C; Schröder JM
Acta Neuropathol; 2003 Apr; 105(4):365-72. PubMed ID: 12624790
[TBL] [Abstract][Full Text] [Related]
57. Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure.
Papadopoulos DP; Makris TK; Krespi PG; Poulakou M; Papazachou OG; Hatzizacharias AN; Perrea D; Votteas V
Eur Cytokine Netw; 2005 Sep; 16(3):211-4. PubMed ID: 16266862
[TBL] [Abstract][Full Text] [Related]
58. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease.
Cicero AF; Derosa G; Manca M; Bove M; Borghi C; Gaddi AV
Endothelium; 2007; 14(4-5):193-8. PubMed ID: 17922335
[TBL] [Abstract][Full Text] [Related]
59. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
60. Abnormal circulating levels of matrix metalloproteinases and their inhibitors in diabetes mellitus.
Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Ftouhi B; Feki M; Slimane H; Kaabachi N
Clin Lab; 2012; 58(7-8):779-85. PubMed ID: 22997979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
